8 results about "Cerebral Thrombus" patented technology

This paper presents a medical device for treating traumatic brain injury and cerebral thrombosis through electroacupuncture. The device includes a 6-DOF (degree of freedom) mechanical arm, a multifunctional tool tip, an MRI helmet suitable for acupuncture, and magnetic resonance imaging (MRI). The acupuncture robot can insert needles and automatically manipulate specific needles by rotating or vibrating them within a specific frequency range, and can enhance the effect by applying electrical stimulation.

The invention belongs to the technical field of medicines, and particularly relates to application of penicillin tenuipes in preparation of a product for preventing or treating ischemic encephalopathy, cell experiments and animal experiments show that penicillin tenuipes has a good treatment effect on cerebral thrombosis and middle artery embolism, can obviously improve behavioral scores after ischemia, and can be used for preparing a medicine for preventing or treating ischemic encephalopathy. And cerebral thrombus and blood vessel diameter conditions. The penicillin tenuipes also has an anti-inflammatory effect. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

The present application belongs to the technical field of bioengineering, and particularly relates to a tuna fish bone antioxidant oligopeptide and a preparation method thereof.The tuna fish bone antioxidant oligopeptide has good scavenging activity, and has good thermal stability and digestion resistance; the mechanism of action is to promote the release of nitric oxide (NO), improve the levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), catalase (CAT) and total antioxidant capacity (T-AOC), and reduce the levels of malondialdehyde (MDA) and lactate dehydrogenase (LDH); JQYG-1 can protect HUVEC cells from oxidative damage induced by hydrogen peroxide; JQYG-1 can exert an antioxidant effect and protect vascular endothelial cells, and can provide a candidate drug for the prevention and treatment of cardiovascular and cerebrovascular diseases such as hypertension, coronary heart disease, cerebral thrombosis, myocardial infarction, atherosclerosis and heart failure.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and discloses a TCM composition, preparation method, and oral formulation for treating cardiovascular and cerebrovascular diseases of the Qi deficiency and blood stasis type. The TCM composition is made from kudzu root, astragalus root, notoginseng, safflower, chuanxiong rhizome, hawthorn, angelica root, polygonum cuspidatum, licorice root, and salvia miltiorrhiza in specific weight parts. A preferred ratio is 60 parts kudzu root, 60 parts astragalus root, 25 parts notoginseng, 30 parts safflower, 25 parts chuanxiong rhizome, 30 parts hawthorn, 25 parts angelica root, 25 parts polygonum cuspidatum, 10 parts licorice root, and 26 parts salvia miltiorrhiza. It can be used for coronary heart disease, cerebral arteriosclerosis, cerebral thrombosis, hyperlipidemia, or sequelae of cerebral infarction. In preparation, the medicinal materials are cleaned, dried, mixed, and pulverized into a fine powder, passed through a 120-180 mesh sieve, and then formed into water pills using water as a binder. After drying and packaging, the product is obtained. This invention has a scientific formulation and precise proportions, making it suitable for the long-term prevention and treatment of cardiovascular and cerebrovascular diseases of the Qi deficiency and blood stasis type.

The invention relates to a medicine for treating cerebral thrombosis, cerebral thrombosis precursor and cerebral thrombosis sequelae. Comprising the following raw materials in parts by weight: 15-30 parts of astragalus membranaceus, 10-20 parts of ligusticum wallichii, 10-20 parts of radix paeoniae rubra, 10-20 parts of gastrodia elata, 2-5 parts of scorpion, 10-20 parts of pseudo-ginseng, 10-20 parts of rhizoma corydalis, 10-20 parts of radix clematidis, 10-20 parts of earthworm, 10-20 parts of honeysuckle stem, 10-20 parts of ginkgo leaf, 1-3 parts of centipede, 10-20 parts of cassia twig, 2-5 parts of leech and 10-20 parts of herba siegesbeckiae. The traditional Chinese medicine is orally taken and externally applied, and has the effects of dispersing blood stasis, relieving spasm, activating blood, relieving pain, tonifying qi and nourishing blood.

This invention discloses a cerebral thrombosis removal device, comprising an outer cannula, a first catheter, a thrombus fragmentation structure, and an artificial blood vessel. The proximal and distal ends of the outer cannula respectively form a first inlet and a first outlet communicating with a first channel. The first catheter is disposed within the first channel. The thrombus fragmentation structure includes a second catheter and a fragmentation section located distal to the second catheter. The second catheter is movably disposed within the first catheter and can extend from the first outlet to fragment the thrombus at the target lesion site. An aspiration channel is formed inside the second catheter, with its distal opening located near the fragmentation section for aspirating the fragmented thrombus fragments. The artificial blood vessel includes a third catheter, the distal end of which is used to cross the thrombus at the target lesion site to reach a distal blood vessel and deliver blood to temporarily relieve ischemia. This invention's cerebral thrombosis removal device can extend the safe surgical time window.

The invention belongs to the technical field of medicines, and particularly relates to application of novel glycyrrhizol in preparation of products for preventing or treating ischemic encephalopathy, and the ischemic encephalopathy comprises cerebral thrombosis, cerebrovascular stenosis / occlusion and cerebral atherosclerosis. According to the application disclosed by the invention, the novel glycyrrhizol is used for treating the ischemic encephalopathy for the first time, and experiments show that the novel glycyrrhizol has a remarkable treatment effect on the ischemic encephalopathy, can be used for obviously improving behavioral scores, cerebral thrombosis and vascular diameter conditions after ischemia and reducing the volume of cerebral infarction, and has a good treatment effect on cerebral thrombosis and middle artery embolism. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

The invention belongs to the technical field of neural stem cell culture, and particularly relates to neural stem cells for treating cerebrovascular and cerebral thrombosis diseases and a culture method. The neural stem cell culture medium for treating cerebrovascular and cerebral thrombosis diseases comprises: (1) a basic culture medium; (2) cecropin, wherein the concentration of the cecropin in the basic culture medium is 5-10 [mu] g / mL; (3) a plant extract, wherein the concentration of the plant extract in the basic culture medium is 10-20 [mu] g / mL; and (4) bletilla striata exosome, wherein the concentration of the bletilla striata exosome in the basal culture medium is 10-20 [mu] g / mL. According to the culture medium, under the condition that the basic culture medium is added, the cecropin, the plant extract and the bletilla striata exosome are additionally added, through the synergistic effect of the cecropin, the plant extract and the bletilla striata exosome, the value-added stability in the neural stem cell culture process is facilitated, meanwhile, the neural stem cells can keep the cell characteristics of the neural stem cells, and the culture efficiency is improved. The preparation efficiency of the neural stem cells is improved.